What FDA‑approved medication is appropriate for a 14‑year‑old with anxiety and depression?

FDA-Approved Medications for a 14-Year-Old with Anxiety and Depression

For a 14-year-old presenting with both anxiety and depression, fluoxetine is the strongest evidence-based choice, as it is the only SSRI FDA-approved for depression in children/adolescents aged 8 years and older, while escitalopram is FDA-approved for depression in adolescents aged 12-17 years. 1, 2

Specific FDA-Approved Options

For Depression:

• Fluoxetine: FDA-approved for ages 8 years and older for major depressive disorder 1, 2

  • Starting dose: 10 mg daily
  • Effective dose: 20 mg daily
  • Maximum: 60 mg daily 3

• Escitalopram: FDA-approved for ages 12-17 years for major depressive disorder 1

  • Starting dose: 10 mg daily
  • Effective dose: 10 mg daily
  • Maximum: 20 mg daily 3

For Anxiety:

No SSRIs currently have FDA approval specifically for anxiety disorders in pediatric patients 4, though they are widely used off-label with substantial empirical support for effectiveness and safety.

Treatment Algorithm

Step 1: Initial Treatment Selection

Start with fluoxetine 10 mg daily as the first-line pharmacological agent because:

• It has the broadest FDA approval (ages 8+)
• It has the strongest evidence base for both depression and anxiety in this age group 2, 5, 6, 7
• Long half-life permits once-daily dosing and provides buffer against missed doses 4

Step 2: Concurrent Psychotherapy (Essential)

Combine medication with cognitive behavioral therapy (CBT) from treatment initiation:

• CBT plus fluoxetine showed 71% response rate versus 35% with placebo in adolescents 1
• Combination therapy consistently outperforms either treatment alone 8, 9, 10
• Reduces suicidality risk compared to medication monotherapy 10

Step 3: Monitoring Schedule (Critical for Safety)

Week 1: In-person assessment to evaluate:

• Emergence of suicidal ideation or behavior
• Behavioral activation (restlessness, impulsiveness, agitation, insomnia)
• Treatment adherence
• Adverse effects (nausea, headache, insomnia, GI symptoms) 3

Weeks 2-4: Weekly contact (in-person or telephone acceptable) 3

Weeks 6-12: Biweekly assessments

Step 4: Dose Titration

• Week 2-4: If well-tolerated but insufficient response, increase to 20 mg daily
• Week 6-8: Assess for clinically significant improvement (expected by week 6) 4
• Week 12: Maximal improvement expected; if inadequate response, consider increasing to 40-60 mg or switching agents 4

Step 5: If Inadequate Response to Fluoxetine

Switch to escitalopram (also FDA-approved for this age):

• Better tolerated in some patients
• Effective dose typically 10 mg daily
• May have fewer drug interactions 3

Critical Safety Warnings

Black Box Warning for All Antidepressants

All SSRIs carry FDA black-box warning for suicidal thinking and behavior through age 24 1, 4:

• Absolute risk: 1% with antidepressant vs 0.2% with placebo
• Risk difference: 0.7% (Number Needed to Harm = 143)
• However, Number Needed to Treat for response = 3 4
• Risk is highest in first months of treatment and following dose changes

Behavioral Activation

More common in younger adolescents and anxiety disorders 4:

• Manifests as: motor restlessness, insomnia, impulsiveness, disinhibited behavior, aggression
• Typically occurs early in treatment or with dose increases
• Usually improves quickly with dose reduction
• Distinguish from mania/hypomania (which appears later and persists)

Contraindications

• Concurrent MAOI use (all SSRIs) 3
• Do not start at high doses (increases self-harm risk) 3

Common Pitfalls to Avoid

1. Starting without psychotherapy: Medication alone has lower efficacy and higher suicidality risk than combination treatment 1, 8, 10

2. Inadequate monitoring: The FDA warning exists because of real risk—weekly contact in first month is non-negotiable 3

3. Rapid dose escalation: SSRIs show logarithmic response with maximal improvement by week 12; slow titration avoids exceeding optimal dose and reduces behavioral activation 4

4. Abrupt discontinuation: All SSRIs require slow taper to avoid withdrawal effects 3

5. Using paroxetine as first-line: Not recommended to be started in primary care due to higher side effect burden 3

6. Ignoring the inherent risk of untreated depression: The risk of doing nothing exceeds the risk of treatment 5

Duration of Treatment

Continue medication for at least 6-12 months after response to prevent relapse:

• Significantly fewer relapses occur with medication continuation versus discontinuation 3
• Longer continuation periods (up to 51 weeks studied) show sustained benefit 3